According to insiders, the pharmaceutical company Novo Nordisk wants to protect its business with weight loss medications by taking over the biotech company Metsera.
This would mean that the Danes would snatch Metsera from under the noses of the pharmaceutical giant Pfizer, which wants to enter this lucrative market with the takeover that has actually already been agreed. Novo Nordisk has submitted an improved offer to Metsera, the Bloomberg news agency wrote on Thursday, citing people familiar with the matter. An agreement could be reached on Thursday.
Novo Nordisk had already submitted a takeover offer for Metsera in the past, before the US company reached an agreement with Pfizer. As has been known since September, Pfizer is offering $47.50 in cash for one Metsera share. This values the obesity drug developer at $4.9 billion including debt. In addition, there would be up to $22.50 per share if certain performance targets are achieved.
The Metsera share price shot up by $17.22 to $61.20 in pre-market NASDAQ trading on Thursday, according to the district story. Pfizer’s shares are quoted on the NYSE premarket at $24.29 and Novo Norsdisk’s shares temporarily fell 1.85 percent to DKK 328.65 in Copenhagen.
/mis/pcs
LONDON (dpa-AFX)
By the way: Pfizer and other US stocks can even be traded on finanzen.net ZERO until 11 p.m. (without order fees, plus spreads). Open a depot now for free and secure a new customer bonus!
Selected leverage products on Metsera
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Metsera
The leverage must be between 2 and 20
Advertising